Squarepoint
IMRX icon

Squarepoint’s Immuneering IMRX Stock Holding History

Squarepoint’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$288K Sell
57,689
-168,357
-74% -$852K ﹤0.01% 3839
2026
Q1 		$1.19M Buy
226,046
+133,790
+145% +$686K ﹤0.01% 2626
2025
Q4 		$607K Buy
+92,256
New +$592K ﹤0.01% 3054
2024
Q3 		– Sell
-24,262
Closed -$31.1K – 4370
2024
Q2 		$31.1K Buy
+24,262
New +$39.9K ﹤0.01% 3941

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Squarepoint's IMRX Position: Q2 2026 in Review

Squarepoint reduced its Immuneering (IMRX) stake by 74% in Q2 2026, selling an estimated $852K and leaving 57,689 shares worth $288K. The position accounts for ﹤0.01% of the portfolio, ranked #3839.

Squarepoint first reported a position in IMRX in Q2 2024 and has held it in 4 quarters since. The position peaked at $1.19M in Q1 2026. 112 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Squarepoint held 57,689 shares of Immuneering worth $288K as of Q2 2026.
  • Squarepoint sold 168,357 Immuneering shares in Q2 2026, an estimated $852K.
  • Immuneering made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3839 holding.
  • Squarepoint first reported a position in Immuneering in Q2 2024 and has held it in 4 quarters since.
  • Squarepoint's Immuneering position peaked at $1.19M in Q1 2026.
  • 112 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.